{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihmpvziutfj3msuu55i27kkp36qjma2w2gtxe3ghu7sbrflf2guzy",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3mn55h2ul4gw2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreibnbbiprl7qbpevztwmor5xrdayfe6ijfw6mlwgl3sagye5anfoby"
    },
    "mimeType": "image/jpeg",
    "size": 12221
  },
  "path": "/2026/05/30/the-results-of-phase-iii-optitrop-lung05-study-of-sacituzumab-tirumotecan-sac-tmt-presented-as-an-asco-oral-presentation-and-simultaneously-published-in-the-lancet/",
  "publishedAt": "2026-05-30T14:01:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "CHENGDU, China, May 30, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”, 6990.HK) announced today that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, the results of the Phase III clinical study OptiTROP-Lung05, evaluating the company’s TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870)(佳泰莱®) in combination with […]",
  "title": "The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet"
}